SNTI

Senti Bioscience

• TipRanks·04/01 21:34

  Senti Biosciences Plans Tax-Free Holding Company Reorganization

• Benzinga·04/01 20:42

  Senti Biosciences Announces Holding Company Reorganization Effective By April 16, 2026; Upon Effectiveness Of Holding Company Reorganization, Senti Biosciences Holdings Would Become Successor Issuer To Co

• Reuters·04/01 20:34

  Senti Biosciences plans tax-free holding company reorganization by April 16

• Reuters·04/01 20:33

  SENTI BIOSCIENCES, INC: UPON EFFECTIVENESS OF HOLDING COMPANY REORGANIZATION, SENTI BIOSCIENCES HOLDINGS WOULD BECOME SUCCESSOR ISSUER TO CO

• Reuters·04/01 20:33

  SENTI BIOSCIENCES INC - ANNOUNCES HOLDING COMPANY REORGANIZATION EFFECTIVE BY APRIL 16, 2026 - SEC FILING

• Benzinga·04/01 12:49

  Senti Biosciences Publishes New Peer-Reviewed Research In Cell Systems Demonstrating Its Systematic Framework For Engineering NOT-Gated Chimeric Antigen Receptor Circuits In Both T Cells And Natural Killer Cells

• Reuters·04/01 12:45

  Senti Bio study in Cell Systems advances NOT-gated CAR design for T and NK therapies

• Dow Jones·03/30 12:07

  Senti Biosciences Price Target Cut to $11.00/Share From $13.00 by Chardan Capital

• Dow Jones·03/30 12:07

  Senti Biosciences Is Maintained at Buy by Chardan Capital

• Benzinga·03/30 11:58

  Chardan Capital Maintains Buy on Senti Biosciences, Lowers Price Target to $11

• TipRanks·03/28 03:55

  Buy Rating on SENTI-202 Driven by Strong Early AML Efficacy and De-Risking Regulatory Designations Despite Financing Overhang

• TipRanks·03/27 12:20

  Senti Bio reports Q4 EPS (53c), consensus (47c)

• Benzinga·03/27 12:19

  Senti Biosciences Q4 EPS $(0.53) Misses $(0.48) Estimate, Sales $22.000K Miss $666.667K Estimate

• Reuters·03/27 12:11

  Senti Biosciences Q4 revenue misses analyst estimates

• Seeking Alpha·03/27 12:05

  Senti Biosciences Non-GAAP EPS of -$0.53 misses by $0.06